Explore stories from Atlantic Canada.
- Global miner BHP Group said on Tuesday it had approved an investment of $4.9 billion for stage two of its Jansen potash project in Canada.
This follows BHP's approval of $5.7 billion capital investment for stage one of the Canadian potash project in August 2021. The additional $4.9 billion investment will double Jansen's production capacity to approximately 8.5 million tonnes per annum, BHP said in a statement.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
BHP Group Approves $4.9 Billion Investment for Jansen Potash Project in CanadaGlobal miner BHP Group has announced its approval of a $4.9 billion investment for stage two of the Jansen potash project in Canada, doubling its production capacity.
Lire la suite »
US Losing Credibility on Global Stage Due to Double Standard in Support for IsraelA US congresswoman criticizes the country's double standard in its level of support for Israel, stating that it is causing the US to lose credibility on the global stage. She highlights the disparity in the US approach towards Russia's attacks on Ukraine compared to its unwavering support for Israel's attacks on Gaza.
Lire la suite »
Treasury Department's Borrowing Plan Takes Center Stage as Fed Policy Statement LoomsInvestors are eagerly awaiting the Treasury Department's new borrowing plan, which will reveal the extent to which longer-term debt will be sold to fund a widening budget deficit. The plan comes hours ahead of the Federal Reserve's interest-rate decision.
Lire la suite »
GSK says endometrial cancer drug meets primary goal in late-stage trialExplore stories from Atlantic Canada.
Lire la suite »
GSK's Cancer Drug Jemperli Shows Positive Results in Late-Stage TrialBritish drugmaker GSK announced that its cancer drug Jemperli has achieved the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.
Lire la suite »